NewAmsterdam Pharma Company NV Target Price

See NewAmsterdam Pharma Company NV's analyst price targets ($51) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$22.58

Average Target Price

$51.33

127.3% upside

3 analysts in the last 4 months

High: $58 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-20	BMO Capital	$58	156.9% upside
2026-07-20	JefferiesDennis Ding	$45	99.3% upside
2026-06-30	RBC Capital	$51	125.9% upside
2026-02-19	Guggenheim	$45	99.3% upside
2026-01-21	RBC Capital	$47	108.1% upside
2026-01-06	Leerink PartnersRoanna Ruiz	$55	143.6% upside
2025-12-02	Goldman Sachs	$37	63.9% upside
2025-10-20	H.C. WainwrightJoseph Pantginis	$52	130.3% upside
2025-08-25	Wells Fargo	$45	99.3% upside
2025-03-03	UBS	$41	81.6% upside
2024-12-30	H.C. WainwrightEd Arce	$48	112.6% upside
2024-11-20	Leerink PartnersRoanna Ruiz	$45	99.3% upside
2024-09-23	Piper SandlerYasmeen Rahimi	$37	63.9% upside
2024-08-28	NeedhamSerge Belanger	$36	59.4% upside

NewAmsterdam Pharma Company NV (NAMS) FAQ

NewAmsterdam Pharma Company NV posts a target price of $51. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $51 for NAMS means covering analysts, on average, see the stock 127.3% upside of $22.58 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for NAMS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; NewAmsterdam Pharma Company NV's other metric pages and overview cover the third.